Opendata, web and dolomites

THERADNET SIGNED

International NETwork for training and innovations in THErapeutic RADiation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 THERADNET project word cloud

Explore the words cloud of the THERADNET project. It provides you a very rough idea of what is the project "THERADNET" about.

acquired    integrating    irradiated    disease    sectors    radiotherapy    biological    metabolism    health    outstanding    therapy    performed    surrounding    radiation    optimized    countries    science    premises    tissues    despite    cured    radiobiological    translational    45    death    combined    standard    approximately    combatting    alone    substantial    dose    therapeutic    personalized    close    resistance    cancer    employability    academia    normal    training    outcome    patients    students    radiobiology    international    benefit    improvements    regrowth    tumor    metastatic    community    modalities    pursuit    adverse    widen    outgrowth    dampen    guarantee    reactions    treatment    intrinsic    co    60    clinical    innovative    models    medicine    microenvironment    cooperate    recurrence    critical    hypotheses    precision    care    network    innovations    successful    limiting    biologically    understand    immune    plasticity    altered    integration    window    prior    small    expertise    innovation    industry    50    primary    individual    collaborations    multimodality    situation    stimulate    mass   

Project "THERADNET" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT ZURICH 

Organization address
address: RAMISTRASSE 71
city: ZURICH
postcode: 8006
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 4˙026˙324 €
 EC max contribution 4˙026˙324 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2023-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT ZURICH CH (ZURICH) coordinator 562˙553.00
2    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 606˙345.00
3    INSTITUT CURIE FR (PARIS) participant 549˙604.00
4    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 531˙239.00
5    UNIVERSITE CATHOLIQUE DE LOUVAIN BE (LOUVAIN LA NEUVE) participant 512˙640.00
6    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 505˙576.00
7    UNIVERSITAETSKLINIKUM ESSEN DE (ESSEN) participant 505˙576.00
8    WESTDEUTSCHES PROTONENTHERAPIEZENTRUM ESSEN (WPE) GGMBH DE (ESSEN) participant 252˙788.00

Map

 Project objective

Radiotherapy alone or in multimodality approaches is applied in 45-60% of all cancer patients, but despite technical innovations approximately only 50% are cured. Disease recurrence may be due to regrowth of the primary tumor or metastatic outgrowth. Intrinsic and acquired resistance of the tumor and adverse reactions in the co-irradiated surrounding normal tissues dampen a successful therapy outcome. Substantial improvements are now expected from biologically optimized, personalized radiotherapy. This network is built on the premises that integration of novel-emerging radiobiological and tumor-biological concepts into current standard-of-care will improve outcome of radiotherapy-treated cancer patients. As the field of radiobiology is small in individual countries, it is essential to cooperate on the European level to achieve a critical mass for innovation in research and training. The partners in this network will stimulate outstanding science to understand the plasticity of an altered tumor metabolism and tumor microenvironment, including the immune system, prior to, and in response to radiotherapy, as well as related dose-limiting adverse effects in normal tissues. Research and development of novel combined treatment modalities in these areas will be performed in models as close as possible to the clinical situation to evaluate their potential to widen the therapeutic window beyond standard-of-care. Students will benefit from outstanding expertise and collaborations within academia and industry integrating novel concepts into translational cancer and radiation research. This will guarantee high employability in various sectors of cancer research and precision medicine. The European community will benefit from the pursuit of innovative hypotheses, training of new researchers, and dissemination of knowledge. By combatting a major death-related disease in Europe, this project will raise health and bring long-term benefit to the European and international community.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERADNET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERADNET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

PARACAT (2019)

Paramagnetic Species in Catalysis Research. A Unified Approach Towards Heterogeneous, Homogeneous and Enzyme Catalysis

Read More  

ARCH (2019)

AGE-RELATED CHANGES IN HEMATOPOIESIS

Read More  

DELIVER (2019)

DELIVERy of advanced therapies for diabetes training network

Read More